The Fly

Medtronic price target lowered to $95 from $100 at Mizuho

Mizuho analyst Anthony Petrone lowered the firm’s price target on Medtronic to $95 from $100 and keeps a Buy rating on the shares. The analyst updated medtech and diagnostics models ahead of the Q4 earnings season to reflect feedback from last week’s West Coast broker conference and ongoing hospital/physician channel checks. The general tone suggested the elevated respiratory viral volumes did not impact inpatient volumes, although some pockets of weakness did emerge in outpatient elective procedures, the analyst tells investors in a research note.

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on MDT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More